Infection due to colistin-resistant Enterobacteriacae in critically-ill patients

Journal of Infection in Developing Countries

Volumn 7, Issue 10, 2013, Pages 713-719

  Garbati, Musa Abubakar ^a   Bin Abdulhak, Aref ^b   Baba, Kamaldeen ^a   Sakkijha, Hussam ^a  

^a KING FAHAD MEDICAL CITY   (Saudi Arabia)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Colistin resistance; Enterobacteriacae; Saudi Arabia

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFALOTIN; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; CLINICAL ARTICLE; COMORBIDITY; CRITICALLY ILL PATIENT; CROSS-SECTIONAL STUDY; DEATH; DIABETES MELLITUS; DISK DIFFUSION; ENTEROBACTERIACEAE; EXTERNAL OTITIS; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OBSERVATIONAL STUDY; PROVIDENCIA STUARTII; RETROSPECTIVE STUDY; RISK FACTOR; SERRATIA MARCESCENS; URINARY TRACT INFECTION;

AGED; ANTI-BACTERIAL AGENTS; COLISTIN; CRITICAL ILLNESS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SAUDI ARABIA;

EID: 84885771519     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.2851     Document Type: Article

References (23)

1. Kontopidou F, Plachouras D, Papadomichelakis E, Koukos G, Galani I, Poulakou G, Dimopoulos G, Antoniadou A, Armaganidis A, Giamarellou H (2011) Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect 17: e9-e11.
2. Beno P, Krcmery V, Demitrovicova A (2006) Bacteraemia in cancer patients caused by colistin-resistant Gram-negative bacilli after previous exposure to ciprofloxacin and / or colistin. Clinical Microbiol Infect 12: 496-500.
3. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A (2005) Outcome of infections due to pandrug-resistant Gram-negative bacteria. BMC Infect Dis 5: 24.
4. Al-Tawfiq JA (2006) Increasing antibiotic resistance among isolates of Escherichia coli recovered from inpatients and outpatients in a Saudi Arabian Hospital. Infect Control Hosp Epidemiol 27: 748-753.
5. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G (2006) Effectiveness and nephrotoxicity of intravenous colistin for the treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 25: 596-599.
6. Lee J, Patel G, Huprikar S, Calfee DP, Jenkins SG (2009) Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 47: 1611-1612.
7. Urban C, Bradford PA, Tuckman M, Segal-Maurer S, Wehbeh W, Grenner L, Colon-Urban R, Mariano N, Rahal JJ (2008) Carbapenem-resistant Escherichia coli harboring Klebsiella pneumonia carbapenemase b-lactamases associated with long-term care facilities. Clin Infect Dis 46: e127-130.
8. Souli M, Galani I, Antoniadou A, Papadomichelakis E, Poulakou G, Panagea T, Vourli S, Zerva L, Armaganidis A, Kanellakopoulou K, Giamarellou H (2010) An outbreak of infection due to beta-lactamase Klebsiella pneumonia carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 50: 364-373.
9. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A (2007) Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 26: 504-507.
10. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, Bonomo RA (2009) Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 53: 3628-3634.
11. Clinical and Laboratory Standards Institute (2009) Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. Approved standard M100-S19 Clinical and Laboratory Standards Institute, Wayne, PA.
12. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, valid from 2012-01-01.
13. Kontopidou F, Plachouras D, Papadomichelakis E, Koukos G, Galani I, Poulakou G, Dimopoulos G, Antoniadou A, Armaganidis A, Giamarellou H (2011) Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect 17: e9-e11.
14. Matthaiou DK, Michalopoulos A, Rafailidis PI, Karageorgopoulos DE, Papaioannou V, Ntani G, Samonis G, Falagas ME (2008) Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 36: 807-811.
15. Mentzelopoulos SD, Pratikaki M, Platsouka E, Kraniotaki H, Zervakis D, Koutsoukou A, Nanas S, Paniara O, Roussos C, Giamarellos-Bourboulis E, Routsi C, Zakynthinos SG (2007) Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa. Intensive Care Med 33: 1524-1532.
16. Cox CE, Harrison LH (1970) Intravenous sodium colistimethate therapy of urinary tract infections: pharmacological and bacteriological studies. Antimicrob Agents Chemother 10: 296-302.
17. Fekety FR Jr, Norman PS, Cluff LE (1962) The treatment of Gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann Intern Med 57: 214-229.
18. Memish ZA, Shib AM, Kambal AM, Ohaly YA, Ishaq A, Livermore DM (2012) Antimicrobial resistance among non-fermenting Gram-negative bacteria in Saudi Arabia. J Antimicrob Chemother 67: 1701-1705.
19. Al-Arfaj AA, Ibrahim ASS, Somily AM Al-Salamah AA (2011) Genetic basis of carbapenem resistance in Acinetobacter clinical isolates in Saudi Arabia. African Journal of Biotechnology 10: 14186-14196.
20. Littlewood JM, Koch C, Lambert PAHøiby N, Elborn JS, Conway SP, Dinwiddie R, Duncan-Skingle F (2000) A ten year review of colomycin. Respir Med94: 632-640.
21. Antoniadou A, Kontopidou F, Poulakou G, Koratzanis E, Galani I, Papadomichelakis E, Kopterides P, Souli M, Armaganidis A, Giamarellou H (2007) Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 59: 786-790.
22. Li J, Nation RL, Turnidge JD Milne RW, Coulthard K, Rayner CR, Paterson DL (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6: 589-601.
23. Chen S, Hu F, Zhang X, Xu X, Liu Y, Zhu D, Wang H (2011) Independent emergence of colistin-resistant Enterobacteriaceae clinical isolates without colistin treatment. J Clin Microbiol 49: 4022-4023.